Hydroxyurea (Hydrea)

04/01/2018 - "Significant reduction in morbidity and mortality have been documented in patients with sickle cell disease (HbSS) by most of the studies using hydroxyurea at a dose of 25-35 mg/kg/day or maximum tolerated dose. "
02/01/2024 - "Hydroxyurea is highly effective in sickle cell disease, but it is still underutilized. "
12/01/2018 - "Although hydroxyurea is proven effective in treatment of sickle cell anemia (SCA) and is widely prescribed in high-income countries, due to questions about feasibility of treating large numbers of patients in resource-limited health systems, its use is limited in sub-Saharan Africa (SSA), where most children with SCA live. "
04/01/2013 - "Hydroxyurea (HU) is highly effective treatment for sickle cell disease (SCD). "
07/01/1997 - "Children with sickle cell anemia provide the best opportunity to assess the efficacy of hydroxyurea (HU) in preventing complications and progressive organ damage. "

01/01/2023 - "Sickle cell is also an important global contributor to stroke burden, but hydroxyurea can be a cost effective medication for stroke prevention in children. "
12/01/2015 - "The efficacy of hydroxyurea in preventing conversion from conditional to abnormal TCD (≥200 cm/sec), which confers a higher stroke risk, has not been studied prospectively in a randomized trial. "
01/01/2023 - "The administration of hydroxyurea was effective for normalizing the blood cell count and preventing stroke recurrence. "
02/01/2024 - "Hydroxyurea holds promise in preventing recurrent strokes in children with SCA, though its efficacy and safety profiles vary among individuals. "
04/01/2023 - "We aimed to estimate stroke risk in children with sickle cell anaemia in Tanzania and to determine the efficacy of hydroxyurea to decrease and prevent stroke. "

11/01/2007 - "Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT)."
10/01/2015 - "We aimed to evaluate the effect of hydroxyurea on clinical and haematological improvement in children with thalassemia intermedia. "
04/01/2015 - "Safety and efficacy of hydroxyurea in children and adolescents with sickle/beta-thalassemia: two-year experience."
01/01/2015 - "Hydroxyurea as a first-line treatment of extramedullary hematopoiesis in patients with beta thalassemia: Four case reports."
03/01/2006 - "Due to genetic heterogeneity of beta-thalassemia (beta-thal) patients, several efforts have been undertaken to determine the efficacy of hydroxyurea treatment. "

02/01/1998 - "To manage the current case of polycythemia vera, hydroxyurea was effective for the control of hematocrit and transfusion of platelet concentrates was effective for hemostasis."
01/01/2018 - "Patients with polycythemia vera (PV), and those treated with hydroxyurea, showed statistically significant increases in eGFR (1.59; 95% CI, 0.28 to 2.90; p = 0.02 in PV; and 1.55; 95% CI, 0.56 to 2.54; p = 0.02 in treatment with hydroxyurea). "
03/01/2024 - "Hydroxyurea (HU) is a commonly used first-line treatment in patients with polycythemia vera (PV). "
01/22/2024 - "Previous studies have suggested that patients with polycythemia vera (PV) who exhibit hydroxyurea-resistance (HU-R) and -intolerance (HU-I) may have distinct characteristics and clinical outcomes. "
01/01/2020 - "Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study."

04/01/2023 - "Efficacy of Hydroxyurea in Transfusion-Dependent Major β-Thalassemia Patients: A Meta-Analysis."
06/01/2015 - "Low and fixed dose of hydroxyurea is effective and safe in patients with HbSβ(+) thalassemia with IVS1-5(G→C) mutation."
12/01/2021 - "Long-term safety and efficacy of hydroxyurea in patients with non-transfusion-dependent β-thalassemia: a comprehensive single-center experience."
07/01/2011 - "Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia."
04/01/2023 - "The keywords used to search for relevant studies included "hydroxyurea", "thalassemia", "transfusion-dependent", and "efficacy". Outcomes assessed in the present meta-analysis included transfusion in one year and intervals between transfusions (in days). "